In vitroactivity of commercial probioticLactobacillusstrains against uropathogenicEscherichia coli | Zendy

Michèle Delley | Zendy; Anne Bruttin | Zendy; Michel Richard | Zendy; Michael Affolter | Zendy; Enea Rezzonico | Zendy; Wolfram Manuel Brück | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitroactivity of commercial probioticLactobacillusstrains against uropathogenicEscherichia coli

Author(s) -

Michèle Delley,

Anne Bruttin,

Michel Richard,

Michael Affolter,

Enea Rezzonico,

Wolfram Manuel Brück

Publication year - 2015

Publication title -

fems microbiology letters

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.899

H-Index - 151

eISSN - 1574-6968

pISSN - 0378-1097

DOI - 10.1093/femsle/fnv096

Subject(s) - probiotic , microbiology and biotechnology , escherichia coli , genitourinary system , gastrointestinal tract , lactobacillus , biology , in vitro , urinary system , bacteria , endocrinology , biochemistry , genetics , anatomy , gene

Urinary tract infection (UTI) is one of the most prevalent infections in humans. In ≥80% of cases, the etiologic agents are strains of uropathogenic Escherichia coli (UPEC), which commonly reside in the gastrointestinal tract. Lactobacilli have been shown to prevent UTI reoccurrence by restoring the urogenital microbiota when administered vaginally or orally. The goal of this study was to determine if commercial probiotic Lactobacillus spp. reduce or clear UPEC in vitro. Results show that it is likely that lactobacilli may, in addition to restoring a healthy urogenital microbiota through acidification of their environment, also displace adhering UPEC and cause a reduction of infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research